You are here: Home » Companies » News
Business Standard

Sun enters vaccine space with dengue shot

This is the second tie-up between the International Centre for Genetic Engineering and Biotechnology and Sun Pharmaceuticals

Veena Mani  |  New Delhi 

Sun Pharma ropes in Mitsubishi Tanabe to distribute products in Japan

has entered the business with an antidote for all four serotypes of dengue.

The company will develop this vaccine on transfer by the transferred of its patent. will tie up with manufacturing units to produce the vaccine because it does not have separate facilities for this purpose.



This is the second tie-up between the and Sun Pharmaceuticals. Earlier this year, the two had collaborated to develop a pill for dengue. The partners said while the pill was meant to treat dengue, the vaccine would help prevent the disease.

The companies did not divulge how much investment had gone into developing the vaccine and pill, which are in the primary stages of development, but said their prices would be affordable. The markets is targeting for the vaccine are the US, Europe and Japan.

According to the agreement, will fund and  support further development of the vaccine candidate and existing patents of the International Centre for Genetic Engineering and Biotechnology, which will grant exclusive rights for development and commercialisation of the vaccine globally.

Sun Pharmaceuticals, which invests over $300 million annually on research and development, will use its expertise as well as that of its associate company Artes Biotechnology, in development of the vaccine. Artes Biotechnology will offer its proprietary know-how in production of from yeast production cell lines. 

“Our collaboration with the for developing an affordable vaccine is part of our commitment to developing and drugs against flaviviruses that are of significant health importance to India and the rest of the world,” said Kirti Ganorkar, executive vice-president and head of global business development at Sun Pharmaceuticals.

Initial findings indicate the International Centre for Genetic Engineering and Biotechnology’s vaccine candidate induces serotype-specific non-cross-reactive and neutralising antibodies without disease-enhancing concerns. These features differentiate it from other vaccine programmes.

“Despite recent approval of a vaccine and several candidates being at advanced stage of clinical trials, the development of a safe, affordable and efficacious vaccine still faces major challenges,” said Dr Salunke, director of the International Centre for Genetic Engineering and Biotechnology.

“Our pre-clinical data is encouraging and this could be an ideal vaccine candidate for all target populations,” he added.

RECOMMENDED FOR YOU

Sun enters vaccine space with dengue shot

This is the second tie-up between the International Centre for Genetic Engineering and Biotechnology and Sun Pharmaceuticals

This is the second tie-up between the International Centre for Genetic Engineering and Biotechnology and Sun Pharmaceuticals has entered the business with an antidote for all four serotypes of dengue.

The company will develop this vaccine on transfer by the transferred of its patent. will tie up with manufacturing units to produce the vaccine because it does not have separate facilities for this purpose.

This is the second tie-up between the and Sun Pharmaceuticals. Earlier this year, the two had collaborated to develop a pill for dengue. The partners said while the pill was meant to treat dengue, the vaccine would help prevent the disease.

The companies did not divulge how much investment had gone into developing the vaccine and pill, which are in the primary stages of development, but said their prices would be affordable. The markets is targeting for the vaccine are the US, Europe and Japan.

According to the agreement, will fund and  support further development of the vaccine candidate and existing patents of the International Centre for Genetic Engineering and Biotechnology, which will grant exclusive rights for development and commercialisation of the vaccine globally.

Sun Pharmaceuticals, which invests over $300 million annually on research and development, will use its expertise as well as that of its associate company Artes Biotechnology, in development of the vaccine. Artes Biotechnology will offer its proprietary know-how in production of from yeast production cell lines. 

“Our collaboration with the for developing an affordable vaccine is part of our commitment to developing and drugs against flaviviruses that are of significant health importance to India and the rest of the world,” said Kirti Ganorkar, executive vice-president and head of global business development at Sun Pharmaceuticals.

Initial findings indicate the International Centre for Genetic Engineering and Biotechnology’s vaccine candidate induces serotype-specific non-cross-reactive and neutralising antibodies without disease-enhancing concerns. These features differentiate it from other vaccine programmes.

“Despite recent approval of a vaccine and several candidates being at advanced stage of clinical trials, the development of a safe, affordable and efficacious vaccine still faces major challenges,” said Dr Salunke, director of the International Centre for Genetic Engineering and Biotechnology.

“Our pre-clinical data is encouraging and this could be an ideal vaccine candidate for all target populations,” he added.
image
Business Standard
177 22

Sun enters vaccine space with dengue shot

This is the second tie-up between the International Centre for Genetic Engineering and Biotechnology and Sun Pharmaceuticals

has entered the business with an antidote for all four serotypes of dengue.

The company will develop this vaccine on transfer by the transferred of its patent. will tie up with manufacturing units to produce the vaccine because it does not have separate facilities for this purpose.

This is the second tie-up between the and Sun Pharmaceuticals. Earlier this year, the two had collaborated to develop a pill for dengue. The partners said while the pill was meant to treat dengue, the vaccine would help prevent the disease.

The companies did not divulge how much investment had gone into developing the vaccine and pill, which are in the primary stages of development, but said their prices would be affordable. The markets is targeting for the vaccine are the US, Europe and Japan.

According to the agreement, will fund and  support further development of the vaccine candidate and existing patents of the International Centre for Genetic Engineering and Biotechnology, which will grant exclusive rights for development and commercialisation of the vaccine globally.

Sun Pharmaceuticals, which invests over $300 million annually on research and development, will use its expertise as well as that of its associate company Artes Biotechnology, in development of the vaccine. Artes Biotechnology will offer its proprietary know-how in production of from yeast production cell lines. 

“Our collaboration with the for developing an affordable vaccine is part of our commitment to developing and drugs against flaviviruses that are of significant health importance to India and the rest of the world,” said Kirti Ganorkar, executive vice-president and head of global business development at Sun Pharmaceuticals.

Initial findings indicate the International Centre for Genetic Engineering and Biotechnology’s vaccine candidate induces serotype-specific non-cross-reactive and neutralising antibodies without disease-enhancing concerns. These features differentiate it from other vaccine programmes.

“Despite recent approval of a vaccine and several candidates being at advanced stage of clinical trials, the development of a safe, affordable and efficacious vaccine still faces major challenges,” said Dr Salunke, director of the International Centre for Genetic Engineering and Biotechnology.

“Our pre-clinical data is encouraging and this could be an ideal vaccine candidate for all target populations,” he added.

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard